Accordingly, knockdown of CHRM3 in GBOs from three patients with two distinct short hairpin RNAs (shRNAs) in the presence of acetylcholine decreased GBO size by 96 h post-transduction compared to a scrambled control (Figure S2H), supporting the role of CHRM3 as a therapeutic target for GBM. The gene discussed is CHRM3; the disease is glioblastoma.